Cargando…
suPARnostic: an advanced predictive tool for detecting recurrence in renal cell carcinoma
BACKGROUND: Plasma soluble urokinase-type Plasminogen Activator Receptor (suPAR) predicts disease aggressiveness in renal cell carcinoma (ccRCC), but its prognostic accuracy has not been investigated. To investigate the prognostic accuracy of preoperative plasma suPAR in patients who received curati...
Autores principales: | Azawi, Nessn, Mosholt, Karina Sif Sondergaard, Fryd, Nathalie Demuth, Lund, Lars, Brignone, Juan Ignacio, Hvid, Nanna, Wulf-Johansson, Helle, Pedersen, Ole Birger Vesterager, Saekmose, Susanne Gjørup, Dabestani, Saeed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594785/ https://www.ncbi.nlm.nih.gov/pubmed/37875832 http://dx.doi.org/10.1186/s12894-023-01337-z |
Ejemplares similares
-
suPARnostic(® )as a treatment efficacy monitoring tool in systemic inflammatory response syndrome/sepsis patients
por: Eugen-Olsen, Jesper, et al.
Publicado: (2008) -
The prognostic value of the suPARnostic(® )ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms
por: Schneider, Uffe V, et al.
Publicado: (2007) -
Unilateral Ultrasound-Guided Transversus Abdominis Plane Block After Nephrectomy; Postoperative Pain and Use of Opioids
por: Azawi, Nessn H., et al.
Publicado: (2016) -
Lifestyle and Clinical Factors in a Nationwide Stage III and IV Renal Cell Carcinoma Study
por: Azawi, Nessn, et al.
Publicado: (2023) -
Renal cell carcinomas mass of <4 cm are not always indolent
por: Azawi, Nessn H., et al.
Publicado: (2017)